Incyte Corp
(NAS:INCY)
$
69.91
0.07 (0.1%)
Market Cap: 13.47 Bil
Enterprise Value: 11.73 Bil
PE Ratio: 499.36
PB Ratio: 4.25
GF Score: 89/100 Incyte Corp at Guggenheim Securities Inflammation & Immunology Conference Transcript
Nov 07, 2023 / 06:10PM GMT
Release Date Price:
$54.72
(+0.27%)
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
All right. Great. So welcome to the fireside chat with Incyte this afternoon. My name is Michael Schmidt. I'm a biotech analyst with Guggenheim. It's my great pleasure to welcome Herve Hoppenot, CEO; as well as Jim Lee, who heads the [IAI] portfolio at Incyte. Welcome, and thanks for joining us.
Herve Hoppenot
Incyte Corporation - CEO & Chairman
Well, thanks for inviting us.
James H. Lee
Incyte Corporation - Group VP, Head of Inflammation & AutoImmunity Group
Thank you. Nice to be here.
Questions & Answers
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
So maybe just starting out with a broader question. We'd like to focus on the IAI portfolio today, perhaps more so than oncology. But with Opzelura, you've sort of set the stage to the commercial product launching at the moment to expand your
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot